Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches

被引：672

作者：

Wu, Qiong

Yang, Zhiping

Nie, Yongzhan

Shi, Yongquan

Fan, Daiming

机构：

[1] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Peoples R China

[2] Fourth Mil Med Univ, Xijing Hosp, Xijing Hosp Digest Dis, Xian 710032, Peoples R China

来源：

CANCER LETTERS | 2014年 / 347卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Biomarker; Cancer; Chemotherapy; Lab approach; Mechanism; Multi-drug resistance (MDR); PLANT SECONDARY METABOLITES; P-GLYCOPROTEIN INHIBITOR; DRUG RESPONSE ASSAY; GASTRIC-CANCER; CELL-LINE; OVARIAN-CANCER; TOPOISOMERASE-II; STEM-CELLS; EXPRESSION; PROTEIN;

D O I：

10.1016/j.canlet.2014.03.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer chemotherapies. The mechanisms of MDR and the approaches to test MDR have been discovered, yet not fully understood. This review covers the in vivo and in vitro approaches for the detection of MDR in the laboratory and the mechanisms of MDR in cancers. This study also envisages the future developments toward the clinical and therapeutic applications of MDR in cancer treatment. Future therapeutics for cancer treatment will likely combine the existing therapies with drugs originated from MDR mechanisms such as anti-cancer stem cell drugs, anti-miRNA drugs or anti-epigenetic drugs. The challenges for the clinical detection of MDR will be to find new biomarkers and to determine new evaluation systems before the drug resistance emerges. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：159 / 166

页数：8

共 81 条

[1]

Agrawal M, 2003, CLIN CANCER RES, V9, P650

[2]

Al-Ali H., 2004, Assay Guidance Manual

[3]

Azab F., 2014, BRIT J HAEMATOL

[4] DNA Damage and Repair in Human Cancer: Molecular Mechanisms and Contribution to Therapy-Related Leukemias [J].